Succeeding at the ‘Harder’ Side of Change: The ‘ABCs’ of High-Performance Behavior

Abstract

It was an increasingly familiar story. A well-established and successful biopharma production site, accustomed to large, relatively stable production volumes for blockbuster products, was starting to see the effects of wider changes in the industry: products going off patent, fewer products coming through the R&D pipeline, and a shift from churning out blockbusters to ramping up new smaller products and supporting increasingly competitive post-loss of exclusivity products. These macro trends were creating new pressures for the manufacturing site such as reduced and more volatile demand, less certainty about future volumes, much more intense cost pressure, and even more of a need to deliver the highest possible levels of quality and safety.